Characterisation of steady‐state pharmacokinetics and glucodynamics of once‐weekly insulin efsitora alfa in individuals with type 2 diabetes

Documenti analoghi

• Once‐weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme
  di: Richard M. Bergenstal, et al.
  Pubblicazione: (2024)
• Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus
  di: Yun Wang, et al.
  Pubblicazione: (2025)
• Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 1 diabetes
  di: Ulrike Hövelmann, et al.
  Pubblicazione: (2024)
• Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China
  di: Xichen Tong, et al.
  Pubblicazione: (2026)
• Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4 , a novel once‐weekly basal insulin, in healthy participants: A randomized trial
  di: Chengyong Tang, et al.
  Pubblicazione: (2025)